At a glance
(thousands of €, if not stated otherwise) |
Three months ended 31 March 2021 |
Three months ended 31 March 2020 |
Year ended 31 December 2020 |
||||||
|---|---|---|---|---|---|---|---|---|---|
Income Statement(*) |
|
|
|
||||||
Revenues |
113,892 |
94,817 |
478,053 |
||||||
Other income |
10,266 |
8,743 |
52,207 |
||||||
R&D expenditure |
(129,960) |
(115,453) |
(523,667) |
||||||
S, G&A expenses |
(44,996) |
(34,325) |
(185,225) |
||||||
Operating expenses |
(174,956) |
(149,778) |
(708,892) |
||||||
Operating loss |
(50,798) |
(46,218) |
(178,632) |
||||||
Net financial results |
38,125 |
(5,705) |
(131,143) |
||||||
Taxes |
(157) |
(336) |
(1,226) |
||||||
Net loss from continuing operations |
(12,830) |
(52,258) |
(311,001) |
||||||
Net profit from discontinued operations, net of tax |
22,191 |
1,657 |
5,565 |
||||||
Net profit/loss (–) |
9,361 |
(50,601) |
(305,436) |
||||||
Balance Sheet |
|
|
|
||||||
Cash and cash equivalents |
2,553,950 |
2,743,573 |
2,135,187 |
||||||
Current financial investments |
2,560,743 |
2,978,805 |
3,026,278 |
||||||
R&D incentives receivables |
142,304 |
115,240 |
135,728 |
||||||
Assets |
5,615,059 |
5,992,406 |
5,717,731 |
||||||
Shareholders’ equity |
2,701,462 |
2,840,041 |
2,670,355 |
||||||
Deferred income |
2,698,417 |
2,913,398 |
2,809,133 |
||||||
Other liabilities |
215,180 |
238,968 |
238,242 |
||||||
Cash Flow |
|
|
|
||||||
Operational cash burn(**) |
(127,669) |
(83,398) |
(517,404) |
||||||
Cash flow used in operating activities |
(121,209) |
(68,874) |
(427,336) |
||||||
Cash flow generated from investing activities |
499,859 |
929,640 |
757,288 |
||||||
Cash flow generated from financing activities |
478 |
3,930 |
22,040 |
||||||
Increase in cash and cash equivalents |
379,129 |
864,695 |
351,994 |
||||||
Effect of currency exchange rate fluctuation on cash and cash equivalents |
31,750 |
17,261 |
(70,539) |
||||||
Cash and cash equivalents at end of the period |
2,553,950 |
2,743,573 |
2,143,071 |
||||||
Cash and cash equivalents from continuing operations |
2,553,950 |
2,743,573 |
2,135,187 |
||||||
Cash and cash equivalents classified as assets held for sale |
- |
- |
7,884 |
||||||
Current financial investments at the end of the period |
2,560,743 |
2,978,805 |
3,026,278 |
||||||
Total current financial investments and cash and cash equivalents at the end of the period |
5,114,693 |
5,722,378 |
5,169,349 |
||||||
Financial Ratios |
|
|
|
||||||
Number of shares issued at end of the period |
65,511,581 |
64,819,022 |
65,411,767 |
||||||
Basic income/loss (–) per share (in €) |
0.14 |
(0.78) |
(4.69) |
||||||
Diluted income/loss (–) per share (in €) |
0.14 |
(0.78) |
(4.69) |
||||||
Share price at end of the period (in €) |
66.12 |
181.00 |
80.48 |
||||||
Total group employees at end of the period (number)(***) |
1,328 |
1,130 |
1,489 |
||||||
|
|||||||||
Employees per site as of 31 March 2021
(total: 1,328 employees)
